LONDON, Feb. 3 (UPI) — Intermittent exercise with and without low oxygen concentrations can improve insulin sensitivity in those with type 2 diabetes, British researchers found.
Go here to read the rest:
Diabetes helped by any exercise
30-01-2012 06:54 Steve Cooksey who runs the popular low-carb diabetes health blog called “Diabetes Warrior” at www.diabetes-warrior.net was notified on Friday, January 27, 2011 that he is under investigation for providing illegal nutritional counseling for people with diabetes on his web site. In this exclusive interview, Jimmy Moore from “The Livin’ La Vida Low-Carb Show” speaks with Steve about what could quite possibly turn into a lawsuit over the free speech rights of those who advocate for alternative health when the conventional wisdom of registered dietitians and the American Diabetes Association has failed so miserably. Listen to “The Livin’ La Vida Low-Carb Show with Jimmy Moore” www.thelivinlowcarbshow.com
Read the rest here:
Low-Carb Diabetes Blogger Steve Cooksey Being Investigated By NC Dietitians – Video
PHOENIX, AZ– – In an effort to support individuals with Type 1 and Type 2 diabetes , Diabetes Lifestyle Coach Marianne Tetlow and Phoenix endocrinologist Dr. Chandana Mishra, are hosting a free family-friendly …
See the article here:
Phoenix Diabetes Lifestyle Coach and Endocrinologist Host Free, Informative Event for Families
FRIDAY, Feb. 3 (HealthDay News) — Diabetes is associated with hearing loss in women, especially if the blood sugar disease isn't well-controlled, new research indicates.
The study, done by researchers at Henry Ford Hospital in Detroit, examined the medical records of 990 men and women who had hearing tests between 2000 and 2008. Patients with diabetes were divided into two groups: well-controlled and poorly controlled.
Among women aged 60 to 75, hearing loss was 14 percent worse even in well-controlled diabetics compared to those without diabetes. That is not a clinically significant loss, noted study author Dr. Kathleen Yaremchuk, chairwoman of the department of otolaryngology at the Henry Ford Healthcare System in Detroit.
“An individual might not notice it,” Yaremchuk said.
On the other hand, poorly controlled diabetics' hearing was 28 percent worse than the non-diabetic group's hearing.
Younger women who had diabetes, well-managed or not, were more likely to have hearing loss than those unaffected by the illness, the study found.
Diabetes is known to affect the eyes, kidneys and other organs, Yaremchuk said. “Our study shows it can affect hearing as well.”
In the study, presented recently at the Triological Society's annual meeting in Miami Beach, Fla., there was no link between hearing loss among men and diabetes, whether it was well-managed or not. Men are more likely in general to suffer from hearing loss than women, so the prevalence of the condition among males may mask diabetes' effect, the study suggested.
Men are exposed to more environmental causes of hearing loss, such as loud noise, either in the workplace or during leisure activities, such as attending large sporting events, explained Yaremchuk.
Managing diabetes properly should help prevent hearing loss or keep it from getting worse, Yaremchuk said.
What's unknown is if better management of diabetes can reverse hearing loss that's already occurred.
“We do not know if losing weight and improving control of diabetes will reverse the hearing loss that is seen. However, it will stop progression of the hearing loss,” she said.
Recommendations call for diabetics' to have their vision checked every year, said Dr. Spyros Mezitis, a clinical endocrinologist at Lenox Hill Hospital in New York City.
This latest finding suggests diabetics may also need to have their hearing tested, Mezitis said.
“This study will help make doctors more aware to ask about hearing, particularly in women between 60 and 75,” said Mezitis, also an assistant professor of clinical medicine at New York Presbyterian Hospital-Cornell Medical Center.
About 26 million Americans have diabetes, mostly type 2, which is associated with obesity.
Because this study was presented at a medical meeting, the conclusions should be viewed as preliminary until published in a peer-reviewed journal.
More information
To learn more about diabetes, visit U.S. National Institutes of Health.
Go here to see the original:
Diabetes Takes Toll on Women's Hearing: Study
Public release date: 2-Feb-2012
[ | E-mail | Share ]
Contact: Rachel Ewing
raewing@drexel.edu
215-895-2614
Drexel University
PHILADELPHIA (February 1, 2012)? Rates of diabetes vary widely across developing countries worldwide, according to a new analysis led by Dr. Longjian Liu of Drexel University's School of Public Health.
Worldwide, four in five people with diabetes now live in developing countries. Liu's study found that access to healthcare support for diabetes varied widely in developing countries, and that one in 10 diagnosed cases remain untreated. The study is available online and will appear in a future issue of the journal Diabetic Medicine.
“Diabetes is now one of the most common non-communicable diseases globally,” Liu said. “It is the fourth or fifth leading cause of death in most high-income countries and there is substantial evidence that it is epidemic in many low- and middle-income countries.” The number of people with diabetes is expected to increase substantially in coming decades.
Many past studies have measured rates of diabetes in developing countries in isolation using different methods, leaving researchers unable to make direct comparisons between countries. Liu's team analyzed data from the World Health Organization's World Health Survey, one of the first and largest global surveys using a standard method to measure the rates of chronic conditions in multiple countries worldwide. Liu's team included a total of more than 215,000 participants from 49 countries in their analysis. The countries represent a variety of regions, including Africa, the Americas, Europe, South-East Asia and the Western Pacific.
The prevalence of diabetes varied widely, from a low of 0.27 percent in Mali, to 15.54 percent in Mauritius. Researchers noted that age is a common factor in diabetes; the low rate observed in Mali may reflect that country's low life expectancy due to infectious diseases.
The study results showed that so-called “adverse body weight” — being underweight, overweight or obese — was associated with increased risk of diabetes. People with diabetes who were underweight were the most likely to go untreated.
Liu and colleagues noted that it is important to identify and address the lack of treatment because diabetes is an independent risk factor for additional health problems and complications, including heart and kidney diseases. Such complications “are resulting in increasing disability, reduced life expectancy and enormous health costs for virtually every society,” Liu said.
Liu's continuing research focuses on the epidemiology and prevention of diabetes and cardiovascular disease. Important next steps include examining risk factors for diabetes and finding effective ways to control these risk factors, including personal health behaviors, social and environmental factors.
###
Full citation: Liu, L., Yin, X., & Morrissey, S. Global variability in diabetes mellitus and its association with body weight and primary healthcare support in 49 low- and middle-income developing countries. Diabetic Medicine. DOI: 10.1111/j.1464-5491.2011.03549.x
[ | E-mail | Share ]
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Read this article:
Diabetes rates vary widely in developing countries, 1 in 10 cases untreated
27-01-2012 10:02 NBA Fit continues to support Dribble to Stop Diabetes in partnership with the American Diabetes Association and Sanofi US. For more information, check out: www.dribbletostopdiabetes.com.
Follow this link:
Join Bob Lanier in Spreading the Word About Dribble to Stop Diabetes – Video
DexCom, Inc. , a leader in continuous glucose monitoring systems, announced today that it has entered into a Development and Commercialization Agreement with Tandem Diabetes Care, Inc.
See more here:
DexCom and Tandem Diabetes Care Announce CGM Development and Commercialization Agreement
ALEXANDRIA, VA–(Marketwire -02/02/12)- The American Diabetes Association announced today that Robert E. Ratner, MD, FACP, FACE has been named Chief Scientific and Medical Officer, effective May 7, 2012. Dr. Ratner is currently Professor of Medicine at Georgetown University Medical School and Senior Research Scientist at the MedStar Health Research Institute in metropolitan Washington, DC.
As Chief Scientific and Medical Officer for the American Diabetes Association, Dr. Ratner will serve as the primary medical and scientific representative and spokesperson for the Association's scientific and medical affairs, research program and other clinical activities, and oversee the planning, development, and implementation of a wide variety of strategic scientific and medical programs to support and advance the Association's mission.
“Bob Ratner is one of the brightest and most respected minds in diabetes,” said Larry Hausner, Chief Executive Officer, American Diabetes Association. “He brings a remarkable breadth of experience to this vital role, and I am confident that his leadership and vision will be a strong guiding force in helping the Association achieve our strategic priorities and further our mission.”
In addition to his roles at Georgetown and MedStar, Ratner is a Principle Investigator for the Diabetes Prevention Program (DPP) and DPP Outcomes Study of the National Institutes of Health (NIH), serving on the Steering Committee for the project nationwide. He currently serves as an Associate Editor of the Journal of Clinical Endocrinology and Metabolism and recently completed a sabbatical as a Robert Wood Johnson Foundation Health Policy Fellow, having served as the study director for the Institute of Medicine Comparative Effectiveness Research Priorities Committee, and a program examiner for health reform in the Health Division of the U.S. Office of Management and Budget.
Ratner received his medical degree from Baylor College of Medicine in Houston, Texas where he also completed his internal medicine training. He underwent fellowship training in endocrinology and metabolism at Harvard Medical School and the Joslin Diabetes Center in Boston. His research interests include diabetes therapeutics and complications, with an emphasis on translational efforts from controlled trials into community-based practice. He is the author of over 120 original scientific articles and 20 book chapters.
For the next three months, Dr. Ratner will be transitioning out of his current position, during which time Sue Kirkman, MD, Senior Vice President, Medical Affairs and Community Information, will be the Association's acting Chief Scientific and Medical Officer.
The American Diabetes Association is leading the fight to Stop Diabetes and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, our mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit www.diabetes.org. Information from both these sources is available in English and Spanish.
Continue reading here:
American Diabetes Association Names Robert E. Ratner, MD, FACP, FACE as Organization's Chief Scientific and Medical …
NEW YORK (Reuters Health) – People who have been infected with the ulcer-causing bacteria Helicobacter pylori are more than twice as likely to develop diabetes later on as people who do not have signs of the infection, according to a new study of Latino adults in California. The results don't prove that the bug causes diabetes, but “it is strongly related to predicting type 2 diabetes,” said …
Continue reading here:
Ulcer-causing bug tied to higher diabetes risk
COPENHAGEN, Denmark (AP) — Sales of its blockbuster diabetes drug helped boost fourth-quarter profits at Danish pharmaceutical company Novo Nordisk AS by 19 percent.
The world's biggest insulin maker said net profit in the last three months of 2011 reached 4.68 billion kroner ($825 million), up from 3.95 billion kroner in the same period of 2010.
Quarterly sales rose 12 percent to 18.12 billion kroner ($3.2 billion) from 16.12 billion.
Chief Executive Lars Rebien Soerensen said Thursday that 2011 “had been a very positive year,” and said the Copenhagen-based group saw “significant progress for our portfolio of clinical development projects.”
For 2012, it said it expects a sales growth of 7 to 11 percent, which is about 4 percentage points higher than initially expected.
See the original post here:
Novo Nordisk results soar on diabetes drug sales
Rates of diabetes vary widely across developing countries worldwide, according to a new analysis led by Dr. Longjian Liu of Drexel University's School of Public Health. Worldwide, four in five people with diabetes now live in developing countries. Liu's study found that access to healthcare support for diabetes varied widely in developing countries, and that one in 10 diagnosed cases remain …
WEDNESDAY, Feb. 1 (HealthDay News) — The latest trial of a drug called GAD-alum to treat type 1 diabetes failed to show any significant improvement in the common markers of the blood sugar disease.
See the rest here:
Type 1 Diabetes Treatment Disappoints in Trial
INDIANAPOLIS and ALEXANDRIA, Va., Feb. 1, 2012 /PRNewswire/ — Lilly Diabetes today announced its commitment to send 89 children to diabetes camp this summer through a collaboration with the American Diabetes …
TUESDAY, Jan. 31 (HealthDay News) — A pre-pregnancy diet high in animal fat increases the risk that moms-to-be will develop gestational diabetes, a new study says.
“Our findings indicate that women who reduce the proportion of animal fat and cholesterol in their diets before pregnancy may lower their risk for gestational diabetes during pregnancy,” senior author Dr. Cuilin Zhang, of the epidemiology branch at the U.S. National Institute of Child Health and Human Development, said in an NIH news release.
Researchers analyzed data from more than 13,000 women in the U.S. Nurses' Health Study II. The women were ages 22 to 45 when they enrolled in the study and provided information every few years about their health and lifestyle habits, such as the kinds of foods they ate.
About 6 percent said they had been diagnosed with gestational diabetes, a form of diabetes that occurs during pregnancy. Gestational diabetes increases the risk for certain pregnancy complications and health problems in newborns.
Women who consumed the most animal fat were nearly twice as likely to develop gestational diabetes as those who consumed the lowest amounts. Also, women who consumed the highest amounts of dietary cholesterol were 45 percent more likely to develop gestational diabetes than those who consumed the lowest amounts.
There was no increased risk of gestational diabetes among women whose diets were high in total fat or other kinds of fat, said the researchers at the NIH and Harvard University.
They also found that the increased risk for gestational diabetes associated with diets high in animal fat and cholesterol seemed to be independent of other dietary and non-dietary risk factors.
For example, exercise is known to reduce the risk of gestational diabetes. But among pregnant women who exercised, the risk of gestational diabetes was higher among those who consumed higher amounts of animal fat and cholesterol than those who consumed lower levels of those types of fat.
The researchers concluded that changing 5 percent of dietary calories from animal fat to plant-derived sources could reduce a woman's risk of gestational diabetes by 7 percent.
The study was published online Jan. 4 in the American Journal of Clinical Nutrition.
“This is the largest study to date of the effects of a pre-pregnancy diet on gestational diabetes,” first author Katherine Bowers of the NICHD said in the news release. “Additional research may lead to increased understanding of how a mother's diet before and during pregnancy influences her metabolism during pregnancy, which may have important implications for the baby's health at birth and later in life.”
While the study found an association between a high fat diet and gestational diabetes, it did not prove that such a diet causes the condition.
More information
The U.S. Agency for Healthcare Research and Quality has more about gestational diabetes.
View original post here:
Fatty Diet Before Pregnancy Linked to Gestational Diabetes
(Reuters Health) – A new study links the diabetes drug metformin to fewer cases of pancreatic cancer — at least in women — but finds other diabetes medications are associated with a higher risk of the disease.
The differences in medication history among people who did or didn't get pancreatic cancer were small, researchers said, and it's unclear why the drugs might affect cancer risks in men and women differently.
Still, the new finding is in line with previous research suggesting that metformin may decrease the risk of multiple cancers, said Dr. Peter Butler, a diabetes researcher at the University of California, Los Angeles David Geffen School of Medicine, who wasn't involved in the new study.
“One theme that seems to be coming through… is that the oldest drug we have for diabetes, metformin, is undoubtedly the best drug we have for diabetes,” he told Reuters Health.
Like us on Facebook
Pancreatic cancer is relatively rare as far as cancers go, but progresses quickly; most people don't survive more than a couple years after diagnosis. The National Cancer Institute estimates that about 44,000 people will be diagnosed with pancreatic cancer in the United States this year, and close to 38,000 will die from the disease.
Research has suggested that people with pancreatic cancer may have an increased risk of diabetes, but it's unclear how diabetes — and the drugs used to treat it — may affect pancreatic cancer risks in previously cancer-free people.
To help answer that question, Dr. Christoph Meier of the University Hospital Basel in Switzerland and his colleagues consulted a database of more than eight million people in the UK, including about 2,800 who were diagnosed with pancreatic cancer between 1995 and 2009.
For each of those people, they found another six of the same age and gender that didn't have pancreatic cancer to serve as a comparison group.
Using records from primary care doctors, the researchers determined how many people in the pancreatic cancer and cancer-free groups had previously been diagnosed with diabetes and were on an anti-diabetes drug, such as metformin or sulfonylureas, which include glimepiride and glyburide.
Those drugs cause the body to make or absorb less glucose (metformin) or to produce more insulin (sulfonylureas) to keep blood sugar levels in check.
One in nine people with pancreatic cancer had a prior diagnosis of diabetes, compared to about one in twelve in the cancer-free comparison group, according to findings published Tuesday in the American Journal of Gastroenterology.
According to their medical records, two percent of people with pancreatic cancer had been taking metformin long-term before they were diagnosed, compared to 1.6 percent of the group without cancer — a difference that could have been due to chance.
But when the researchers separated the records by gender, they found that significantly fewer women with a new diagnosis of pancreatic cancer had been taking metformin for at least a few years, compared to cancer-free women.
That was after the researchers had already taken into account whether women were overweight or obese and if they smoked or drank alcohol.
The association in one gender but not the other was “somewhat unexpected,” according to Meier's team, and there's no clear biology-based way to explain why metformin might help protect women against pancreatic cancer, but not men.
The findings were reversed for insulin and sulfonylureas in the study population. Significantly more people with pancreatic cancer had a history of long-term use of those drugs than cancer-free people.
Craig Currie, who has studied diabetes drugs and cancer at the Cardiff University School of Medicine in the UK, said it makes sense that insulin and sulfonylureas would increase the risk of pancreatic cancer. Insulin promotes cancer growth, he said, and also acts directly on the pancreas.
The study's investigators “raise doubts about these treatments,” he told Reuters Health in an email.
“There is a possibility that exogenous insulin (insulin that's not made naturally by the body) is of questionable safety in people with type 2 diabetes,” added Currie, who didn't participate in the new research.
Still, absolute differences in medication use were small even in people with cancer: less than one percent of those with or without pancreatic cancer had taken insulin long-term. Sulfonylurea users accounted for just over three percent of people with a new pancreatic cancer diagnosis and two percent without cancer.
Butler said it's hard to tease out what cancer risks may be due to the drugs, and what could be a result of poor diet and lack of exercise, for example, in people with diabetes. He said that more research will be needed to tease out those specific effects.
“Honestly for patients at this point, I think this is another piece of the jigsaw puzzle,” Butler said.
“This paper in itself would not cause me to recommend a change in treatment for people.”
That said, Butler concluded that evidence suggests most people with type 2 diabetes who don't have any medical reasons not to take metformin should be on the drug, either alone or in combination with other anti-diabetes medications.
SOURCE: bit.ly/kkA6Tc American Journal of Gastroenterology, online January 31, 2012.
See the rest here:
Diabetes Drug Linked to Pancreatic Cancer Risk
NEW YORK (Reuters Health) – Overweight women with diabetes may be able to cut their risk of urine leakage if they shed some pounds, a new study suggests.
Extra pounds, especially in the belly, are considered a risk factor for urinary incontinence. And some studies have found that when overweight women drop even a modest amount of weight, they can curb their risk of incontinence.
Type 2 diabetes, which often goes hand-in-hand with obesity, is also a risk factor for urine leakage, regardless of weight. So weight loss could be especially helpful for heavy women with diabetes — but studies hadn't looked at the question until now.
In the new study, researchers found that overweight diabetic women who took up diet and exercise changes lost an average of 17 pounds over a year. And with the weight loss came a lower risk of developing incontinence.
Over a year, 10.5 percent of women in the diet-and-exercise group developed new problems with urine leakage. That compared with 14 percent of women who had not made lifestyle changes.
“Overweight and obese women with type 2 diabetes should consider weight loss as a way to reduce their risk of developing urinary incontinence,” lead researcher Suzanne Phelan, of California Polytechnic State University, told Reuters Health by email.
And of course, she added, there are already known benefits of shedding those extra pounds — like better diabetes control and a lower risk of heart disease.
The findings, reported in the Journal of Urology, are based on 2,739 middle-aged and older women who were part of a larger diabetes study.
At the outset, the women were randomly assigned to one of two groups. In one group, the women were encouraged to cut calories and exercise for three hours a week. The other group had three diabetes education sessions.
Overall, women in the lifestyle group had a lower rate of urinary incontinence over the next year. And it didn't take a lot of weight loss to start to make a difference, Phelan's team found.
For every two pounds a woman lost, the odds of developing incontinence dipped by three percent.
On the other hand, weight loss did not seem to help women who already had urine leakage problems at the study's start.
“We aren't sure why weight loss appeared to impact prevention but not resolution of urinary incontinence,” Phelan said.
It's possible, she said, that weight loss is more effective at preventing, rather than treating, urine leakage. Or there may simply have been too few women with existing urinary incontinence to detect an effect of weight loss, Phelan added.
It's also unclear how to account for the drop in incontinence risk — it might be related to the exercise or the blood sugar reduction, for instance.
Urinary incontinence is very common among women — in large part because vaginal childbirth is a major risk factor.
One recent study of U.S. adults found that about 53 percent of women older than 20 said they'd had problems with urine leakage in the past year. That was up from less than half of women surveyed several years earlier.
Researchers said the increase was partly explained by rising rates of diabetes and obesity.
SOURCE: http://bit.ly/zqDrRV Journal of Urology, online January 19, 2012.
More here:
Weight loss may prevent leaky bladder in diabetes
According to a new report, Australian men are becoming obese than women even though they do more exercise.
Read the rest here:
Diabetes doubled over 20 years – report
TUESDAY, Jan. 31 (HealthDay News) — A new Swiss-American study indicates that long-term use of the popular diabetes medication metformin may lower the risk of developing pancreatic cancer, at least among women.
The researchers also found that the long-term use of another class of diabetes medications known as sulfonylureas was associated with a “substantial” bump in pancreatic risk and long-term insulin use was linked to a bump in pancreatic cancer risk in men.
“This result is somewhat unexpected,” the team wrote in its paper, which is published in the Jan. 31 online issue of The American Journal of Gastroenterology.
Pancreatic cancer is the fourth most deadly cancer in the United States, with an overall survival rate of less than 5 percent, even though it is fairly rare, according to the U.S. National Institutes of Health.
The researchers noted that previous research has suggested that metformin may lower the risk for other cancers, breast and ovarian cancer in particular.
To explore metformin's protective potential against pancreatic cancer, the team sifted through drug prescription, diagnostic, hospitalization and fatality information that had been collected by the British “General Practice Research Database.” The data also included significant demographic information, such as smoking, alcohol use and body mass index.
The team honed in on statistics regarding nearly 2,800 patients (all under the age of 90) who had been diagnosed with pancreatic cancer for the first time between 1995 and 2009. Data concerning almost 16,600 patients who did not have pancreatic cancer was used as a comparison.
The result: Short-term use of metformin or sulfonylureas and/or insulin had no appreciable impact on pancreatic cancer risk.
However, long-term use of each of these medications did appear to have a sizeable impact on pancreatic cancer risk among diabetics. While female patients saw their risk go down with metformin treatment and up with sulfonylureas, male patients saw their risk go up with insulin.
Dr. Michael Choti, a professor of surgery and oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University in Baltimore, stressed the “importance of trying to identify causes for a devastating disease that is often diagnosed late.”
“Over the years, many groups have tried to look at a variety of risk factors, dietary and other things, and there have been some reports over the years,” he noted. “But nothing has really panned out well. So this is indeed an interesting study.”
“But it's also important to say,” Choti added, “that while these could be associations, we cannot really say that what we have here is a cause-and-effect. Pancreatic cancer is a multi-factorial disease. So, while it makes sense conceptually that these drugs could have an impact on the pancreas, which is a metabolic organ, it's still too early to be sure what's happening. And it's too early to recommend metformin as a preventive therapy for pancreatic cancer.”
“So this is interesting and important,” he said. “But it's not definitive.”
More information
For more on pancreatic cancer, visit the U.S. National Library of Medicine.
More:
Popular Diabetes Drug Might Cut Pancreatic Cancer Risk: Study
ROCKVILLE, MD–(Marketwire -01/31/12)- MarketResearch.com has announced the addition of the new report “Global Diabetes Devices Market 2010-2014,” to their collection of Medical Devices market reports. For more information, visit http://www.marketresearch.com/Infiniti-Research-Limited-v2680/Global-Diabetes-Devices-6773755/
The report forecast the Global Diabetes Devices market to reach US$20.5 billion in 2014. One of the key factors contributing to this market growth is the global increase in the diabetic population. The Global Diabetes Devices market has also been witnessing the latest insulin delivery systems. However, the process of registration of medical devices could be a challenge to the growth of this market.
Commenting on the report, healthcare analyst said, “The increasing demand for non-invasive devices is leading to the development of new technologies in the Global Diabetes Devices market. The devices that are currently in development use sweat, exhaled breath or a fluorescent signal to measure a patient's blood glucose level, eliminating the painful process of piercing the skin to collect a blood sample for measurement with the current devices. With the application of new technologies, these devices are expected to be more efficacious and reduce errors compared to the currently marketed products.”
According to the report, previously the prices of the diabetes devices were high and were not affordable by the low- and middle-income population. But lately, due to the emergence of modern devices, the prices have reduced up to 50-60 percent, and many patients are now able to afford them, which has driven the market significantly. This driver is expected to have a strong impact on the market.
For more information, visit http://www.marketresearch.com/Infiniti-Research-Limited-v2680/Global-Diabetes-Devices-6773755/
About MarketResearch.com
MarketResearch.com is the leading provider of global market intelligence products and services. With over 300,000 research reports from more than 700 top consulting and advisory firms, MarketResearch.com offers instant online access to the world's most extensive database of expert insights on global industries, companies, products, and trends. For more information, call Veronica Franco at 240-747-3016 or visit www.MarketResearch.com.
See the rest here:
Market Research Projects Diabetes Devices Market at $20 Billion by 2014
Native Americans who often ate processed meat in a can, generically known as “spam” and a common food on reservations, one subsidized by the government — had a two-fold increased risk of developing diabetes over those who ate little or none
Read more:
'Spam' meat tied to diabetes risk in Native Americans, study finds